Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of tns11 in preparation of products for diagnosis and treatment of endometrial cancer

An endometrial cancer, product technology, applied in the field of cancer diagnosis, prognosis prediction, treatment, can solve problems such as treatment and outcome differences

Active Publication Date: 2019-09-10
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the past, it was believed that endometrial cancer has a high 5-year survival rate and is a cancer with a relatively good prognosis. However, if a comprehensive evaluation of the survival data of endometrial cancer patients is carefully conducted, it can be found that even patients with lesions confined to the uterus have better treatment and prognosis. Outcomes are often quite different

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tns11 in preparation of products for diagnosis and treatment of endometrial cancer
  • Application of tns11 in preparation of products for diagnosis and treatment of endometrial cancer
  • Application of tns11 in preparation of products for diagnosis and treatment of endometrial cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1 Gene Chip Screening for Differentially Expressed Genes

[0070] 1. Sample collection:

[0071] Endometrial cancer tissue samples: Patients with endometrial cancer were collected, all of whom underwent surgical treatment, and 10 surgical paraffin specimens were collected. All patients were diagnosed with endometrial cancer by pathological examination. Other enrollment conditions are: all patients have not received any treatment before admission; no other malignant tumors; no other hormone-related diseases; complete clinical data.

[0072] 10 cases of endometrial cancer patients, the average age of onset was 58 years old. The main clinical manifestations of patients are irregular vaginal bleeding, lower abdominal pain, menstrual disorders, vaginal discharge, etc. There are also some patients who have no obvious symptoms and are found in physical examination. The endometrial cancer specimens were sectioned by HE staining, and the histomorphological diagnosis w...

Embodiment 2

[0084] Example 2 Large sample verification screened out differentially expressed genes

[0085] Considering the gene that has not been studied in the prior art on the correlation between this gene and endometrial cancer as a candidate gene, and considering the results of gene sequencing, the TNS11 gene (its expression is down-regulated in endometrial cancer tissue) was selected for verification .

[0086] 1. Sample collection

[0087] According to the method of Example 1, 50 cases of endometrial cancer tissues and 60 cases of normal endometrial tissues were collected.

[0088] 2. Validation at the mRNA level

[0089] 2.1 Extract tissue RNA

[0090] Step is with embodiment 1.

[0091] 2.2 Reverse transcription

[0092] Using a reverse transcription kit, 1 μg of total RNA was reverse-transcribed with reverse transcription buffer to synthesize cDNA. Use 25μl reaction system, take 1μg total RNA for each sample as template RNA, and add the following components in PCR tubes: D...

Embodiment 3

[0115] Example 3 TNS11 Gene Overexpression

[0116] 1. Plasmid construction

[0117] Amplification primers are designed according to the coding sequence of TNS11 gene, and the design of primers is well known to those skilled in the art. Amplify the coding sequence of the full-length TNS11 gene from the cDNA library of adult fetal brain (clontech company, article number: 638831), insert the above cDNA sequence into the eukaryotic cell expression vector pcDNA3.1, and connect the obtained recombinant vector pcDNA3.1 -TNS11 was used in subsequent experiments.

[0118] 2. Culture and transfection of endometrial cancer cells

[0119] 2.1 Cell culture

[0120] The Ishikawa3-H-12 cell line was cultured in RPMI 1640 medium (containing 10% fetal bovine serum, 100 U / ml penicillin, 100 g / ml streptomycin) in 50 ml culture flasks, at 37 °C, 5% CO 2 Continuous cultivation in a humidified incubator.

[0121] 2.2 Cell transfection

[0122] 1. The day before transfection, 0.5-2*10 5 Tumo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a diagnosis and treatment target, namely TNS11 gene, for endometrial cancer. By detecting the contents of the TNS11 gene and expression products thereof, in the uterus tissue of a tested object, it can judge whether the tested object is affected by the endometrial cancer or not or it can diagnose whether the risk of the endometrial cancer exists in the tested object or not. In addition, by conducting researches on the proliferation and migration indexes of endometrial cancer cells which are cultured in vitro, it proves that the TNS11 gene can serve as a drug target for treating the endometrial cancer.

Description

technical field [0001] The present invention relates to the fields of cancer diagnosis, treatment, and prognosis prediction. More specifically, the present invention relates to a method for cancer diagnosis and prognosis prediction by means of detecting TNS11 abnormality; and a cancer therapeutic agent for activating TNS11 gene or protein. Background technique [0002] Endometrial cancer, also known as uterine body cancer, refers to a group of epithelial malignant tumors that originate in the endometrium, most of which originate in endometrial glands, and are called endometrial adenocarcinoma or endometrioid adenocarcinoma. Endometrial cancer is one of the three common malignant tumors of the female reproductive tract, accounting for about 7% of the total female cancers and 20%-30% of female reproductive tract malignant tumors. In recent years, due to the extension of human life span and the widespread application of exogenous estrogen, the incidence of endometrial cancer ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G01N33/68G01N33/574A61K45/00A61P35/00
Inventor 杨承刚孙锦云边洋
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com